Clinical trials: Minimal Disease, Residual
Colo-rectal Cancer
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive…
- Trial name
- EMPIRE (NCT07058012)
- Testing
- Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075
- Where
- 13 sites in United States
- Volunteers
- 79 people
- Sponsor
- NSABP Foundation Inc
Mantle Cell Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete…
- Trial name
- NCT03267433
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate
- Where
- 375 sites in United States, Saudi Arabia
- Volunteers
- 689 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Acute Myeloid Leukemia
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT.
- Trial name
- NCT01385787
- Where
- 38 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Multiple Myeloma, Minimal Residual Disease
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous…
- Trial name
- MRD (NCT06109233)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- FengYan Jin
Light Chain (AL) Amyloidosis, MRD
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months.
- Trial name
- NCT07215494
- Testing
- First-Line Dara-BorCyD Treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
Large-cell Lymphoma
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line…
- Trial name
- NCT07443137
- Testing
- Rapcabtagene autoleucel (YTB323)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Ovarian Cancer, Primary Peritoneal Cancer
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the pharmacokinetics and pharmacodynamics of cisplatin used as (hyperthermic) intraperitoneal chemoperfusion, as an adjunct to surgery, in…
- Trial name
- OvIP1 (NCT02567253)
- Testing
- Cytoreductive surgery, IPEC with Cisplatin (75mg/m²), IPEC with Cisplatin (100mg/m²)
- Where
- Belgium
- Volunteers
- 56 people
- Sponsor
- University Hospital, Ghent
Colorectal Cancer Stage III, Liver Metastasis Colon Cancer
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- NCT06111105
- Where
- 15 sites in Austria, Denmark and 3 more
- Volunteers
- 590 people
- Sponsor
- Claus Lindbjerg Andersen
Acute Lymphoblastic Leukemia
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs…
- Trial name
- NCT07400029
- Testing
- Obecabtagene Autoleucel
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Cervical Cancer
Perioperative Adebrelimab for Locally Advanced Cervical Cancer
This prospective, single-center, single-arm, phase II study will evaluate perioperative adebrelimab in patients with locally advanced cervical cancer.
- Trial name
- ADE-LACC (NCT07811375)
- Testing
- Adebrelimab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Anhui Provincial Hospital
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA-BLIN-01/PET069014 (BLIN-01)
The PETHEMA Spanish group treats patients with high-risk Philadelphia chromosome-negative ALL, aged 18 to 55 years, based on the MRD clearance as assessed by flow cytometry at a centralised evaluation centre.
- Trial name
- NCT03523429
- Testing
- blinatumomab
- Where
- 12 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, CLL
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
This study seeks to examine the investigational use of the conditioning regimen (bendamustine, fludarabine, and rituximab) prior to haploidentical peripheral blood allogeneic stem cell transplantation with Post-Transplant…
- Conditions
- Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma
- Trial name
- NCT03524235
- Testing
- Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noah Merin
Rectal Adenocarcinoma, Circulating Tumor DNA
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the…
- Conditions
- Rectal Adenocarcinoma, Circulating Tumor DNA, Minimal Residual Disease, Neoadjuvant Chemoradiotherapy
- Trial name
- NCT05969938
- Testing
- MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- WeiWei Xiao
Measurable Residual Disease
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at high risk of relapse
- Trial name
- NCT06000306
- Testing
- Digital Droplet PCR
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Zhejiang University
Uterine Neoplasms, Cervical Cancer
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer.
- Trial name
- NCT07382505
- Testing
- Serial blood collection for MRD testing
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Asan Medical Center
Squamous Cell Carcinoma of Head and Neck
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
- Trial name
- MRD-DUCHESS (NCT06744296)
- Testing
- Blood Draws and Tissue Sample(s)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Colorectal Cancer
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or…
- Trial name
- CLAUDE (NCT05350501)
- Testing
- EO2040
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Enterome
Hematologic Malignancy
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB)…
- Trial name
- HTLP-ONCO (NCT04707300)
- Testing
- Human T Lymphoid Progenitor (HTLP) injection
- Where
- 5 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Follicular Lymphoma
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events.
- Trial name
- FLMRD (NCT04934930)
- Testing
- Bendamustin, Obinutuzumab
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Meir Medical Center
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00863434
- Testing
- clofarabine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington